Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in…
- Trial name
- NCT02284893
- Testing
- Saxagliptin, Dapagliflozin, Sitagliptin
- Where
- 79 sites in United States, Hungary and 4 more
- Volunteers
- 461 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus
The study purpose is to demonstrate the benefit of a simplified version of the DIAMOND System (A third Generation) in comparison to a sham treatment in terms of Glycemic control, measured as A1c, FBG and Post-Prandial Glucose…
- Trial name
- RUBY (NCT01529216)
- Testing
- DIAMOND System
- Where
- 2 sites in France, Netherlands
- Volunteers
- 2 people
- Sponsor
- MetaCure Limited
Elevated Body Mass Index
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)
- Trial name
- NCT02470403
- Testing
- LIK066
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea…
- Trial name
- NCT00575588
- Testing
- Metformin, Sulphonylurea, Saxagliptin
- Where
- 94 sites in Finland, Germany and 9 more
- Volunteers
- 891 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with…
- Trial name
- NCT01084005
- Testing
- linagliptin
- Where
- 34 sites in Australia, Canada and 3 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes.
- Trial name
- AWARD-PEDS (NCT02963766)
- Testing
- Dulaglutide
- Where
- 61 sites in United States, Brazil and 9 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients
This is a multi-center, prospective, open label study of the Duodenal Glycemic Control™ procedure on type 2 diabetes patients sub-optimally controlled, to examine the safety and initial performance of the DiaGone™ system.
- Trial name
- NCT03390322
- Testing
- DiaGone™
- Where
- 3 sites in Czechia, Israel
- Volunteers
- 31 people
- Sponsor
- Digma Medical Ltd.
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
- Trial name
- STELLA-ELDER (NCT02297620)
- Testing
- Suglat®
- Where
- 8 sites in Japan
- Volunteers
- 8,687 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
A Study of LY2189102 in Patients With Type 2 Diabetes
Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.
- Trial name
- NCT00942188
- Testing
- LY2189102
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes.
- Trial name
- NCT05813912
- Testing
- Insulin Icodec, Semaglutide
- Where
- 39 sites in Czechia, Malaysia and 3 more
- Volunteers
- 148 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes Mellitus
The aim of this study is to evaluate safety and effectiveness of treatment with gemigliptin for 24 weeks in Korean patients aged ≥ 65 years with type 2 diabetes mellitus in routine clinical settings
- Trial name
- NCT05281029
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus Combined With Overweight or Obesity
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250…
- Trial name
- NCT07747857
- Testing
- TQF3250 capsules
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.
- Trial name
- NCT01498900
- Testing
- repaglinide
- Where
- Turkey (Türkiye)
- Volunteers
- 30,554 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the the current status of diabetes management, control, and complications in diabetic subjects with type 2 diabetes in Bangladesh.
- Trial name
- DiabCare Asia (NCT01877200)
- Testing
- No treatment given
- Where
- Bangladesh
- Volunteers
- 2,092 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and DPP-4 inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242228
- Testing
- ipragliflozin, DPP-4 inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Astellas Pharma Inc
Diabetic Cardiomyopathies
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
- Trial name
- NCT04083339
- Testing
- AT-001
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 675 people
- Sponsor
- Applied Therapeutics, Inc.
Type 2 Diabetes Mellitus
Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China
DONATE study is a multi-center, prospective cohort, single arm, observational study to be performed in 3000 Chinese type 2 diabetes mellitus (T2DM) patients recruited from 100 tier 2 or 3 hospitals, China.It is a drug intense…
- Trial name
- DONATE (NCT03156985)
- Where
- 83 sites in China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.